Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis

Enrico Franceschi, Giovanna Cavallo, Luciano Scopece, Roberta Degli Esposti, Gabriele Paioli, Anna Paioli, Emanuela Palmerini, Maria Pia Foschini, Anna Federica Marliani, Lucio Crinò

Research output: Contribution to journalArticlepeer-review

Abstract

Herein we describe the case of a patient with primary diffuse leptomeningeal gliomatosis (PDLG). After surgery and ventriculoperitoneal shunt placement, due to poor general conditions, the patient was not eligible for radiotherapy. For this reason we decided to start a systemic chemotherapy treatment with Temozolomide (150 mg/m2 per day for 5 days every 4 weeks). After three cycles a partial response was achieved with a clear improvement of general conditions. In our knowledge, this is the first time that PDLG treatment with Temozolomide has been described.

Original languageEnglish
Pages (from-to)261-264
Number of pages4
JournalJournal of Neuro-Oncology
Volume73
Issue number3
DOIs
Publication statusPublished - Jul 2005

Keywords

  • Chemotherapy
  • Primary diffuse leptomeningeal gliomatosis
  • Temozolomide

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis'. Together they form a unique fingerprint.

Cite this